NCT00613691 2013-10-21A Phase I, Open-label, Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Endothelin B Agonist, SPI-1620, in Patients With Recurrent or Progressive CarcinomaSpectrum Pharmaceuticals, IncPhase 1 Completed36 enrolled